Denali Therapeutics

What an incredible evening celebrating the MPS Society’s 50th Anniversary Masquerade Gala! Congratulations to the National MPS Society on 50 years of unwavering dedication, advocacy, and impact. Your continued leadership has transformed countless lives and inspired a community. Our team was honored to join the Society and so many passionate individuals and families who are committed to supporting those living with mucopolysaccharidosis (MPS) and mucolipidosis (ML). A huge thank you to everyone who came out to celebrate this milestone — your energy, compassion, and commitment continue to move the mission forward.

We were honored to sponsor and join the Cure Sanfilippo Foundation's recent family gathering in Los Angeles. These special events bring together families who understand each other’s journeys, creating a space where children are celebrated for exactly who they are and where families can connect authentically. Thank you to the Cure Sanfilippo Foundation for leading this important work, and to the families who welcomed us—we’re grateful to support the Sanfilippo syndrome community.

Each year, the Tour de Fox Wine Country Ride brings together an incredible community committed to advancing research and raising awareness for Parkinson’s disease. Members of our team were proud to once again join The Michael J. Fox Foundation for Parkinson's Research at this inspiring event. It was energizing to ride alongside so many dedicated individuals and families, all united in the mission to speed breakthroughs and bring hope to those living with Parkinson’s. Thank you to all the riders, supporters, and advocates who made this event so impactful. #TourDeFox #ParkinsonsAwareness 

It was an honor for Denali to join the global community of scientists, clinicians and advocates at the 15th International Congress of Inborn Errors of Metabolism (#ICIEM).    We are energized by the opportunity to share our progress with our TransportVehicle™ platform, designed to deliver medicines across the blood-brain barrier, and to highlight our work advancing potential therapies for individuals living with Hunter syndrome and other lysosomal storage diseases.    ICIEM creates a valuable opportunity to collaborate, listen and learn, and to accelerate the development of investigational medicines that may one day transform lives.

We were proud to join the ALS Network and our South San Francisco neighbors for the 4th annual Splash to Cure ALS! Huge thanks to everyone who braved the ice and brought the energy to raise critical awareness and funds for #ourALScommunity — including our biotech neighbors at Cytokinetics, Corcept Therapeutics, Trace Neuroscience, and BioMarin Pharmaceutical Inc.

Each year, we look forward to attending the National MPS Society Family and Scientific Conference.  This event brings together families, advocates, researchers, and clinicians who are all united by a shared commitment to progress and connection.  We’re especially grateful for the moments of reconnection, the inspiring conversations, and the unwavering drive toward a brighter future. Thank you, National MPS Society, for bringing the community together and fostering such an impactful space for learning and collaboration.

We reported our second quarter 2025 financial results and business highlights. Read our press release here: https://lnkd.in/gcBka-We

Delivering biotherapeutics across the blood-brain barrier has been one of the greatest challenges in the treatment of diseases of the central nervous system, but our understanding of how to overcome this hurdle continues to advance rapidly. In preclinical research appearing in the new issue of Science, Denali researchers show how our TransportVehicle™️ platform delivers an anti-amyloid beta antibody across the blood-brain barrier through a distinct route of entry that could potentially improve the treatment of Alzheimer’s disease. Learn more about this insight and other important results of the study at https://lnkd.in/gt9dBkPj.

Today, we announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) seeking accelerated approval for our investigational enzyme replacement therapy for Hunter syndrome (MPS II). For individuals and their families living with Hunter syndrome, there is an urgent need to treat the whole body, including the brain, to address the full spectrum of the disease.     This is an important milestone for the Hunter syndrome community but also for our mission at Denali to discover and develop medicines that cross the blood-brain barrier for the treatment of rare diseases and neurodegenerative disorders.    Read our news release here: https://lnkd.in/gSB3BkcZ #MPS #HunterSyndrome #RareDisease

May 15th is #InternationalMPSDay — a day we come together with individuals, families, advocates, and all community stakeholders to raise awareness for MPS. The MPS community drives action every day—for earlier diagnoses, improved care, and a future where no one is left behind. We’re pleased to join voices across the global MPS community to raise awareness and drive progress. #ItsAboutTime to unite for MPS.